Ocugen
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Ocugen
Ocugen, Inc. 是一家臨床階段的生物製藥公司，專注於開發治療失明疾病的基因療法。該公司的管道產品包括 OCU400，這是一種新型基因治療候選產品，可恢復視網膜完整性和功能，適用於一系列遺傳多樣的遺傳性視網膜疾病，如色素性視網膜炎和萊伯先天性黑蒙； OCU410，治療乾性年齡相關性黃斑變性（AMD）的基因療法候選者； OCU200，一種處於臨床前開發階段的新型融合蛋白，用於治療糖尿病性黃斑水腫、糖尿病性視網膜病變和濕性 AMD。 Ocugen, Inc.與CanSino Biologics Inc.建立戰略合作夥伴關係，共同開發和製造基因療法；和 Bharat Biotech 用於 COVAXIN 在美國市場的商業化。公司總部位於賓夕法尼亞州馬爾文。
如何購買 Ocugen (OCGN)
登入
1分鐘開戶
僅需1分鐘即可完成帳戶申請和驗證。整個過程完全自助，支援 RockFlow App 和網頁端操作。
充值資金
帳戶驗證完成後，您可以使用首選的支付方式向帳戶充值。
購買 OCGN
透過 RockFlow App 或網頁端搜尋 OCGN，輸入您想要投資的金額，然後點擊確認即可完成交易。
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.